Introduction {#s1}
============

Preeclampsia (PE), characterized by maternal hypertension, proteinuria, and other systemic disorders occurring after 20 weeks of gestation, remains a leading cause of maternal and fetal morbidity and mortality ([@B20]; [@B22]; [@B33]). Upon pregnancy, placenta might be exposed to glucocorticoid (GC) through several ways, including GC metabolism damage, synthetic GC administration and maternal stress ([@B18]; [@B31]). Although the pathogenesis of PE remains largely elusive, increasing evidence indicates that PE is associated with stress or GC exposure ([@B9]; [@B11]; [@B12]; [@B32]; [@B35]). A previous report demonstrated that stress in early pregnancy might lead to an increase in the risk of early-onset PE ([@B12]). Moreover, another report showed that stress in early pregnancy could contribute to PE in rat ([@B27]). Interestingly, we confirmed recently that GC exposure in early placentation could induce PE in rats ([@B35]; [@B36]).

PE is a systemic inflammatory condition in which oxidative stress and endothelial dysfunction occurs ([@B3]). Cotechini et al. showed that inflammation in rat pregnancy inhibits spiral artery remodeling leading to PE-related features and fetal growth restriction ([@B2]), providing the rationale for the use of anti-inflammatory mediators in the prevention and treatment of inflammation-associated PE. It is proposed that PE may occur due to deficiency of polyunsaturated fatty acids (PUFAs) and their anti-inflammatory products specialized pro-resolving mediators (SPMs), including lipoxins, resolvins, protectins, and maresins ([@B3]). As one of the most important endogenous SPMs, ~~L~~lipoxin A~4~ (LXA~4~), derived from arachidonic acid (AA) involving the dual lipoxygenation of arachidonic acid enzymatically by lipoxygenases (LOXs), function as ''stop signal'' in inflammation ([@B25]). It has been demonstrated that LXA~4~ levels are greater in pregnant compared with nonpregnant women, with a progressive increase across pregnancy ([@B17]), and LXA~4~ is a novel estrogen receptor modulator ([@B23]). Together with our findings, increasing studies indicate that LXA~4~ exerts vital roles in homoeostasis restoration and inflammation termination of reproductive system ([@B17]; [@B8]; [@B16]; [@B13]; [@B32]; [@B34]; [@B15]). In fact, we found that PE is linked to a deficiency of LXA~4~ that could improve PE-related symptoms in rat model ([@B13]; [@B32]). Moreover, a previous study by Villa et al. demonstrated the protective roles of aspirin triggered-LXA~4~ (ATL, 15-epi-LXA~4~) on PE-related inflammation ([@B6]). Thus, GC exposure-mediated PE may involve the loss of LXA~4~.

The present study was undertaken to confirm the involvement of GC/LXA~4~ axis in PE pathogenesis and to reveal the underlying mechanisms. We examined whether GC-mediated PE is explained by the dysregulation of LXA~4~ biosynthesis. The modulation of LXA~4~ on Dex-mediated PE was also investigated. The study would provide an important clue for better understanding of PE pathogenesis and contribute to develop potential therapeutic strategies to prevent PE.

Materials and Methods {#s2}
=====================

Reagents and Antibodies {#s2_1}
-----------------------

Dex sodium phosphate, Dex, 3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyltetrazolium bromide (MTT), and Hoechst 33258 were purchased from Sigma Aldrich (Allentown, PA, USA). LXA~4~ solution (Cayman Chemical, Ann Arbor, MI, USA) was preserved at -80°C until diluted in cell culture medium or sterile saline immediately before use. Anti-HIF1A, -ALOX15, -ALOX15B, -β-actin, and -Lamin B antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-ALOX5 monoclonal antibody was from BD Biosciences. Anti-11β-HSD2 antibody was from Biosynthesis Biotechnology Company (Beijing, China). RIPA Lysis Buffer and Nuclear and Cytoplasmic Protein Extraction Kit were from Beyotime Biotechnology (Shanghai, China). BCA Protein Assay Kit was from Pierce (Rockford, IL, USA).

Patient Samples {#s2_2}
---------------

Blood specimens were from 26 pregnant women: 13 pregnant women with PE defined by proteinuria (0.3 g/day) and hypertension (systolic and diastolic blood pressures over 140/90 mmHg) ([@B7]) were recruited from Wuhan Fourth Hospital (Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology); as control group, 13 women were selected with characteristics similar to those presented by PE patients, including gestational age, body mass index, eliminated kidney disease, high blood pressure, diabetes, and so on. Blood and placenta specimens were from diagnosed patients after informed consent and approved by the Medical Ethical Committee of Tongji Medical College, Huazhong University of Science and Technology in accordance with Declaration of Helsinki.

The patients didn't receive any medications before samplings collection. Blood extracted from pregnant women stood for 20 min at room temperature, and was then centrifuged at 4,000 rpm for 5 min for obtaining serum. The serum was stored at -80°C for further detection.

Animals and Experimental Protocols {#s2_3}
----------------------------------

Female Sprague-Dawley rats (10--12 weeks old, weighing 220--250 g) were from the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology. Animals were housed individually in plastic cages with wood chips as bedding under pathogen-free conditions, in a controlled environment of temperature at 20--25°C and 12 h cycles of light and dark. Rats were fed a standard laboratory diet and water *ad libitum*. Pregnancy was obtained by mating female rats with fertile male rats at a ratio of 2:1 overnight. Daily vaginal smears were observed, and appearance of spermatozoa in vaginal smear was defined as gestational day (GD) 1. All animal works were conducted according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All studies involving rats were approved by Animal Care and Use Committee of Huazhong University of Science and Technology.

### Experimental Protocol 1 {#s2_3_1}

Pregnant rats were randomly divided into control group and treatment group. The rats in treatment group were injected subcutaneously (*s.c.*) with Dex sodium phosphate (2.5 mg/kg per day) from GD7 to 13, and control rats were injected *s.c.* with equal saline. On GD21, rats were fully anesthetized with chloral hydrate and placental samples were rapidly extracted. Blood specimens were drawn by heart puncture and centrifuged at 3,000 rpm for 20 min at 4°C to collect the serum.

### Experimental Protocol 2 {#s2_3_2}

Pregnant rats were randomly divided into Control group, Dex group and Dex+LXA~4~ group. From GD7 to GD13, control rats were injected *s.c.* with equal saline, rats in Dex group were injected *s.c.* with Dex sodium phosphate (2.5 mg/kg per day), and rats in Dex+LXA~4~ group were injected with Dex sodium phosphate (2.5 mg/kg per day) *s.c.* plus LXA~4~ (10 μg/kg per day) intraperitoneally (*i.p.*). On GD21, rats were fully anesthetized with chloral hydrate and the uterus was removed and placed in a chilled dish. Placenta and pup were rapidly extracted. All of the pups were weighed, and litter size noted. All samples were analyzed individually.

Measurement of Systolic Blood Pressure (SBP) {#s2_4}
--------------------------------------------

At indicated time (initial non-pregnant status, GD3--5, GD14, and GD20), SBP was detected in conscious and restrained pregnant rats. An automated system with a photoelectric sensor linked to a dual channel recorder (BP-98A, Softron, Japan), tail cuff and sphygmomanometer was used to obtain blood pressure measurements, which have been previously demonstrated to be closely correlated with arterial measurements ([@B19]). The measurements were repeated three times for each rat, with the mean value recorded.

Determination of Urinary Albumin Excretion {#s2_5}
------------------------------------------

On GD5 and GD20, the pregnant rats were placed in metabolic cages for collecting 24 h urine. To avoid contamination of the collected urine, rats were restricted from food; however, they were allowed free access to water. To avoid the adverse effects of fasting, rats were fed in other cages for 30 min every 6 h. Urine samples were centrifuged at 3,000 rpm for 20 min at room temperature, and the supernatant was collected for urinary albumin analysis. Urine protein concentrations were detected by using pyrogallol red in an automatic biochemical analyzer (ADVIA 2400 Chemistry System, Siemens Medical Solutions Diagnostics, NY, USA).

Measurement of Thiobarbituric Acid Reactive Substances (TBARS) {#s2_6}
--------------------------------------------------------------

TBARS in placenta was determined by employing a commercially available kit (QuantiChrom™ TBARS Assay Kit, DTBA-100) according to the manufacturer's instructions (BioAssay Systems, USA). Briefly, placental tissues (20 mg or so) were placed into 200 μl ice-cold phosphate buffered saline with protease inhibitors. The tissues were first homogenized thoroughly and then sonicated for 20 s on ice. The homogenates were then centrifuged at 3,000 rpm for 10 min at 4°C. 20 μl aliquot was used for protein determination. The resultant absorbances were read at 535 nm. TBARS levels were expressed as nmol/mg protein.

Cell Culture and Treatment {#s2_7}
--------------------------

Human first-trimester trophoblast cell line HTR-8/SVneo were from American Type Culture Collection (USA). Cells were cultured at 37°C in a humidified atmosphere with 5% CO~2~ in 1,640 medium supplemented with 10% heat-inactivated fetal bovine serum, 25 mM HEPES, 100 U/ml penicillin G and 100 U/ml streptomycin. Cells were treated with Dex (10 (^-7^) mol/L) or Dex (10^-7^ mol/L) plus LXA~4~ (100 nM) for cell proliferation assay, and Dex (10^-6^ mol/L) or Dex (10^-6^ mol/L) plus LXA~4~ (100 nM) for cell apoptosis assay.

Cell Proliferation and Apoptosis Assay {#s2_8}
--------------------------------------

Cell proliferation was measured by a colorimetric method based upon metabolic reduction of the soluble yellow tetrazolium dye MTT to its insoluble purple formazan. Approximately 5,000 cells/well were grown in 96-well plates and incubated overnight in 200 μl of cell culture medium. After cells were treated with indicated conditions for 24 h, each well was added with

20 μl MTT (0.5 mg/ml) and incubated for 4 h before supernatant was removed. After plate was placed at 37°C for 15 min in 150 μl DMSO, the absorbency was detected with a micro ELISA reader (Amersham Biosciences, USA) at 492 nm.

Cell apoptosis was determined by Hoechst staining. Cells were incubated with Hoechst dye for 15 min before examination under fluorescence microscope. Apoptotic cells were characterized by characteristic nuclear fragmentation; only those nuclei showing evidence of DNA fragmentation without plasma membrane damage were determined to be apoptotic cells.

Western Blotting {#s2_9}
----------------

Total protein and nuclear protein of placental tissue were extracted by using RIPA Lysis Buffer and Nuclear and Cytoplasmic Protein Extraction Kit respectively for assessing different protein expression. Protein concentrations were detected by using BCA Protein Assay Kit. Then, regular western blotting assay was performed. Briefly, equal amounts of protein were subjected to 12% SDS-PAGE electrophoresis and transferred to PVDF membranes (Millipore, USA). The membranes were blocked with 5% (w/v) non-fat dried milk and incubated with different primary antibodies overnight at 4°C, followed by incubation with a HRP-conjugated secondary antibody. The bound antibody was detected by an enhanced chemiluminescence kit (Millipore, USA) on X-ray film. Lamin B and β-actin served as internal control of nuclear protein and total protein respectively.

Measurement of Cortisol, LXA~4~, Leukotriene B4 (LTB~4~), and Corticosterone {#s2_10}
----------------------------------------------------------------------------

Before measurement of cortisol, LXA~4~, LTB~4~, and corticosterone levels in placenta, tissue homogenization was firstly performed to extract the placental tissue contents. Briefly, placental samplings were homogenized in mild homogenate buffer containing a cocktail enzyme inhibitor by using glass homogenizer. 20 min later, the homogenates were centrifuged at 3,000 rpm at 4°C for 20 min. Supernatants were collected and stored at -80°C until detection. The levels of cortisol in serum and placenta were detected by enzyme chemiluminescence immunoassay in chemiluminescence analyzer (ADVIA Centaur XP Immunoassay System, Siemens Healthcare Diagnostics Inc., NY, USA). The levels of LXA~4~ and LTB~4~ in serum and placenta were determined by assay kit according to the manufacturers' protocols (Neogen Corporation, Lansing, MI, USA; Cayman Chemical Company, USA) respectively. Corticosterone in rat placenta was quantified using a commercial ELISA kit for corticosterone (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.

Statistical Analysis {#s2_11}
--------------------

All statistical analyses were performed by using the SPSS 19.0 software. The results were expressed as means ± S.E.M of multiple independent experiments. The means of different groups were compared by employing either Student's t-test or one-way ANOVA followed by S-N-K post-hoc test. A value of p \< 0.05 was considered significant.

Results {#s3}
=======

The Expressions of Cortisol and LXA~4~ in PE Patients {#s3_1}
-----------------------------------------------------

To determine whether GC is correlated with LXA~4~ in PE, we detected the expressions of cortisol and LXA~4~ in placenta of both PE patients and normal pregnancies. As shown in [**Figures 1A, B**](#f1){ref-type="fig"}, the levels of placental cortisol in PE patients showed significant increase compared to normal pregnancies,while placental LXA~4~ levels of PE patients decreased when compared to normal pregnancies. Meanwhile, placental LTB~4~ levels of PE patients were higher than those of normal pregnancies ([**Figure 1C**](#f1){ref-type="fig"}). In line with this, serum LXA~4~ levels of PE patients were lower than those of normal pregnancies and the levels of serum LTB~4~ in PE patients showed increase compared to normal pregnancies, although the levels of serum cortisol in PE patients showed non-significant increase compared to normal pregnancies ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). Importantly, correlation analysis showed that there was significant negative correlation between cortisol and LXA~4~, positive correlation between cortisol and LTB~4~, and negative correlation between LXA~4~ and LTB~4~ ([**Figures 1D--F**](#f1){ref-type="fig"}). Mechanistically, we have confirmed abnormal expressions of LXA~4~ biosynthesis enzymes during PE that both ALOX15 and ALOX15B are downregulated, while ALOX5 is activated in PE patients ([@B15]). Together, these clinical data suggest that LXA~4~ deficiency is associated with GC exposure in human PE.

![Expressions of cortisol and LXA~4~ in human PE. **(A)** Comparison of placental cortisol levels between PE patients and healthy controls; **(B)** Comparison of placental LXA~4~ levels between PE patients and healthy controls; **(C)** Comparison of placental LTB~4~ levels between PE patients and healthy controls; **(D--F)** The correlation between cortisol, LXA~4~ and LTB~4~ in PE patients. Results are expressed as means ± SEM (n=13 in each group). \*\*p \< 0.01 and \*\*\*p \< 0.001 versus control group, two-tailed Student's t-test.](fphar-11-01131-g001){#f1}

GC Exposure Inhibits LXA~4~ Biosynthesis in PE Rats {#s3_2}
---------------------------------------------------

To confirm the involvement of GC/LXA~4~ axis in PE pathogenesis, an GC-mediated PE rat model was constructed as previously ([@B36]), and the levels of LXA~4~ in placenta of experimental PE rats were detected. As shown in [**Figure 2A**](#f2){ref-type="fig"}, placental LXA~4~ was strikingly down-regulated by Dex in experimental PE rats, while placental LTB~4~ levels of PE rats were up-regulated by Dex ([**Figure 2B**](#f2){ref-type="fig"}). To determine the mechanisms underlying the effects of GC on LXA~4~ production, we detected the expressions of ALOX15, ALOX15B and ALOX5 in placenta of experimental PE rats. Dex treatment contributed to the downregulation of both ALOX15 and ALOX15B while the enhancement of ALOX5 nuclear translocation ([**Figure 2C**](#f2){ref-type="fig"}), suggesting GC-mediated disturbance of biosynthesis enzymes may be the reason for LXA~4~ deficiency in PE. These results indicate that GC exposure may lead to PE through dampening LXA~4~ biosynthesis.

![GC inhibits LXA~4~ biosynthesis in experimental PE rats. Pregnant rats were treated according to *Experimental protocol 1*. **(A)** Effect of Dex on placental LXA~4~ levels in pregnant rats; **(B)** Effect of Dex on placental LTB~4~ levels in pregnant rats; **(C)** Effect of Dex on ALOX15, ALOX15B, and ALOX5 protein expression in placenta of pregnant rats. Protein expression was detected by western blotting. The histogram represents means ± SEM of the densitometric scans for protein bands (n=7 rats in each group), normalized by comparison with β-Actin and Lamin B and expressed as a percentage of Control. Results are expressed as means ± SEM (n=7 rats in each group). \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001 versus control group, two-tailed Student's t-test.](fphar-11-01131-g002){#f2}

LXA~4~ Improves PE-Related Symptoms and Placental Oxidative Stress of PE Rats {#s3_3}
-----------------------------------------------------------------------------

To further validate the involvement of GC/LXA~4~ axis in the pathogenesis of PE, the experimental PE rats were treated with LXA~4~. As shown in [**Figure 3A**](#f3){ref-type="fig"}, SBP was elevated after Dex exposure, while blood pressure conditions were improved after LXA~4~ administration. Dex exposure increased the urine protein level on GD20, while LXA~4~ could alleviate the urine protein excretion ([**Figure 3B**](#f3){ref-type="fig"}). LXA~4~ could also ameliorate intrauterine growth restriction as showed by the fetal rat weight ([**Figure 3C**](#f3){ref-type="fig"}) ([**Figure 3D**](#f3){ref-type="fig"}). To clarify the effects of LXA~4~ on placental oxidative stress, placental oxidative damage and HIF1A expression were determined by using TBARS assay kit and western blotting respectively. As shown in [**Figure 3D, E**](#f3){ref-type="fig"}, HIF1A was overexpressed in placenta of experimental PE rats, and Dex exposure contributed to increased TBARS levels in placenta, suggesting placental oxidative impairment. But after LXA~4~ treatment, both TBARS levels and HIF1A expressions were ameliorated ([**Figures 3D, E**](#f3){ref-type="fig"}). These results suggest that LXA~4~ is effective in relieving PE-related symptoms and placental oxidative stress of experimental PE rats induced by GC.

![LXA~4~ ameliorates PE-related symptoms and placental oxidative stress of GC-mediated rat PE. Pregnant rats were treated according to *Experimental protocol 2*. Systolic blood pressure (SBP), 24 h urinary protein excretion and fetal weight are presented in **(A--C)** respectively; **(D)** Effect of LXA~4~ on Dex-mediated placental HIF1A expression. HIF1A was detected by western blotting. The histogram represents means ± SEM of the densitometric scans for protein bands (n=7 rats in each group), normalized by comparison with Lamin B and expressed as a percentage of Control; **(E)** Effect of LXA~4~ on Dex-mediated placental lipid peroxidation. Levels of lipid peroxidation were determined by using a commercially available TBARS kit. The measurements of lipid peroxidation represent the degree of placental oxidative stress. Results are expressed as means ± SEM (n=7 rats in each group). \*\*\*p \< 0.001 versus control group, ^†^P \< 0.05, ^††^P \< 0.01 and ^†††^P \< 0.001 versus Dex group, one-way ANOVA with S-N-K posttest.](fphar-11-01131-g003){#f3}

LXA~4~ Suppresses GC-Mediated ALOX5 Activation and LTB~4~ Upregulation in Experimental PE Rats {#s3_4}
----------------------------------------------------------------------------------------------

ALOX5 is the key enzyme for the biosynthesis of both lipoxins (LXs) and leukotrienes (LTs). Upon stimulation, it translocates onto the nuclear membrane to form active enzyme complex that converts AA to LTs ([@B26]). ALOX5 activation indicates possible class switching from LXs to LTs production that was confirmed by our present results that Dex-mediated ALOX5 activation leaded to increased LTB~4~ but decreased LXA~4~ production in placenta of experimental PE rats ([**Figures 4A, B**](#f4){ref-type="fig"}). However, LXA~4~ treatment could suppress Dex-induced ALOX5 nuclear translocation and LTB~4~ increase in placenta of experimental PE rats ([**Figures 4A, B**](#f4){ref-type="fig"}). These data indicate that LXA~4~ could inhibit GC-mediated ALOX5 activation and LTB~4~ upregulation in placenta of experimental PE rats.

![LXA~4~ inhibits GC-mediated ALOX5 activation and LTB~4~ production in experimental PE rats. Pregnant rats were treated according to *Experimental protocol 2*. **(A)** Effect of LXA~4~ on Dex-mediated placental ALOX5 nuclear translocation. ALOX5 nuclear translocation was detected by western blotting. The histogram represents means ± SEM of the densitometric scans for protein bands (n=7 rats in each group), normalized by comparison with Lamin B and expressed as a percentage of Control; **(B)** Effect of LXA~4~ on Dex-mediated placental LTB~4~ increase. Results are expressed as means ± SEM (n=7 rats in each group). \*\*p \< 0.01 and \*\*\*p \< 0.001 versus control group, ^†^P \< 0.05 and ^††^P \< 0.01 versus Dex group, one-way ANOVA with S-N-K posttest.](fphar-11-01131-g004){#f4}

LXA~4~ Is Involved in 11β-HSD2 Upregulation in Experimental PE Rats {#s3_5}
-------------------------------------------------------------------

Given that 11β-HSD2 has a well recognized function as a potent dehydrogenase that rapidly inactivates GC, and is a key enzyme for controlling local GC activity in placenta ([@B24]; [@B29]; [@B1]), we determined placental 11β-HSD2 changes and the modulation of LXA~4~ on 11β-HSD2 in experimental PE rats. Placental 11β-HSD2 was strikingly decreased by Dex exposure in experimental PE rats, as evaluated by western blotting ([**Figure 5A**](#f5){ref-type="fig"}). In line with this, placental corticosterone levels of PE rats were higher than those of controls ([**Figure 5B**](#f5){ref-type="fig"}). Surprisingly, LXA~4~ could antagonizes the effects of Dex exposure on 11β-HSD2 expressions ([**Figures 5A, B**](#f5){ref-type="fig"}). Therefore, 11β-HSD2 downregulation in placenta might contribute to increases in local GC activity, and LXA~4~ may be involved in the up-regulation of 11β-HSD2 in PE.

![LXA~4~ suppresses GC-mediated 11β-HSD2 expression and corticosterone production in experimental PE rats. Pregnant rats were treated according to *Experimental protocol 2*. **(A)** Effect of LXA~4~ on Dex-mediated placental 11β-HSD2 expression. 11β-HSD2 expression was detected by western blotting. The histogram represents means ± SEM of the densitometric scans for protein bands (n=7 rats in each group), normalized by comparison with β-Actin and expressed as a percentage of Control; **(B)** Effect of LXA~4~ on Dex-mediated placental corticosterone increase. Results are expressed as means ± SEM (n=7 rats in each group). \*\*\*p \< 0.001 versus control group, ^††^P \< 0.01 versus Dex group, one-way ANOVA with S-N-K posttest.](fphar-11-01131-g005){#f5}

LXA~4~ Antagonizes the Effects of GC on Trophoblast Proliferation and Apoptosis {#s3_6}
-------------------------------------------------------------------------------

Dex suppressed the proliferation of trophoblast cell line HTR-8/SVneo, while it stimulated HTR-8/SVneo apoptosis *in vitro* ([**Figures 6A, B**](#f6){ref-type="fig"}). However, LXA~4~ treatment could antagonize the effects of Dex on HTR-8/SVneo proliferation and apoptosis ([**Figures 6A, B**](#f6){ref-type="fig"}). These results suggest that LXA~4~ could improve the adverse effects of Dex on trophoblast development *in vitro*, supporting the protective roles of LXA~4~ on trophoblast against GC.

![LXA~4~ antagonizes the effects of GC on trophoblast proliferation and apoptosis *in vitro*. HTR-8/SVneo cells were treated with Dex (10^-7^ mol/L) or Dex (10^-7^ mol/L) plus LXA~4~ (100 nM) for 24 h in proliferation assay **(A)** and treated with Dex (10^-6^ mol/L) or Dex (10^-6^ mol/L) plus LXA~4~ (100 nM) for 24 h in apoptosis assay **(B)**. **(A)** LXA~4~ reverses the inhibitory effect of Dex on HTR-8/SVneo proliferation; **(B)** LXA~4~ inhibits the promotion effect of Dex on HTR-8/SVneo apoptosis. Results are expressed as means ± SEM from three independent experiments. \*\*P \< 0.01 versus control group, ^†^P \< 0.05 and ^††^P \< 0.01 versus Dex group, one-way ANOVA with S-N-K posttest.](fphar-11-01131-g006){#f6}

Discussion {#s4}
==========

Up to now, the molecular mechanisms underlying the pathogenesis PE remain elusive. The study provides evidence that GC exposure might lead to PE through dampening LXA~4~, an endogenous protective anti-inflammatory and proresolving mediator during pregnancy, supporting that GC/LXA~4~ axis might represent a common pathway through which PE occurs. Meanwhile, our data demonstrate the mechanisms underlying the modulation of LXA~4~ on GC in PE.

The study revealed several novel findings regarding the relationship between GC and LXA~4~ in PE. Foremost, the study reports that LXA~4~ deficiency is associated with GC exposure in human PE, thus providing the clinical data of involvement of GC/LXA~4~ in PE. Furthermore, the experimental PE rat model confirms that GC exposure could result in PE through dampening LXA~4~ biosynthesis, while LXA~4~ could improve PE-related symptoms and placental oxidative stress of experimental PE rats. Lastly, LXA~4~ could inhibit GC-mediated ALOX5 activation and LTB~4~ upregulation in experimental PE rats, and antagonize the effects of GC on11β-HSD2 expression and trophoblast development. Thus, the study is the first to demonstrate that GC exposure induces PE *via* dampening LXA~4~, supporting GC/LXA~4~ axis as a common pathway through which PE occurs.

Increasing evidence indicate the adverse effects of stress or GC exposure on pregnancy ([@B18]; [@B31]; [@B12]; [@B14]). Previous reports showed that stress could induce PE in pregnant women and rats ([@B27]; [@B12]). We confirmed recently that GC exposure in early pregnancy could result in PE-related symptoms in pregnant rats ([@B35]; [@B36]), indicating GC exposure as a potential stimulus for PE development. In the study, pregnant rats exposed to GC were characterized by decreased LXA~4~ expression, suggesting these PE-related manifestations have occurred, at least in part, in response to LXA~4~ down-regulation mediated by GC since LXA~4~ is an endogenous protective anti-inflammatory and proresolving mediator during pregnancy. In fact, cortisol levels were negatively correlated to LXA~4~ levels in PE patients, and LXA~4~ biosynthesis were dampened by GC in PE rats.

LXA~4~ biosynthesis is controlled by several enzymes through transcellular process, enzymatically by LOXs involving the dual lipoxygenation of AA ([@B25]). Recently, we studied the expressions of LXA~4~-biosynthesis enzymes ALOX15, ALOX15B and ALOX5 in PE women, and confirmed the downregulation of ALOX15B and ALOX15 while the activation of ALOX5 ([@B15]). ALOX5 is the key enzyme for the biosynthesis of both LTs and LXs. Upon stimulation, it translocates onto the nuclear membrane to form active enzyme complex that converts AA to LTs ([@B26]). ALOX5 activation indicates possible class switching from LXs to LTs synthesis, which has been confirmed by our previous work that ALOX5 activation resulted in increased LTB~4~ but reduced LXA~4~ production ([@B34]; [@B15]). Here, we showed LXA~4~ deficiency and LTB~4~ increase in PE patients and GC-mediated experimental PE rats. Importantly, we demonstrated negative association between LXA~4~ and GC in PE patients. By employing PE rat model, we demonstrated that GC exposure could inhibit LXA~4~ production *via* downregulating ALOX15 and ALOX15B while activating ALOX5. Thus, GC-mediated inhibition of ALOX15B and ALOX15 while activation of ALOX5 was responsible for abnormal LXA~4~ biosynthesis during PE, providing the evidence supporting the involvement of GC/LXA~4~ axis in PE pathogenesis. We next elucidated the mechanisms determining the counterregulatory effects of LXA~4~ on GC. We found that LXA~4~ could inhibit GC-mediated ALOX5 activation and LTB~4~ upregulation in experimental PE rats. The present study has demonstrated an additional function of LXA~4~ to alleviate the adverse effects of GC during pregnancy by inhibiting ALOX5 activation.

In the study, Dex exposure resulted in proteinuria, hypertension and restricted fetus, all classic hallmarks of PE. Interestingly, LXA~4~ supplementation significantly improved PE-related symptoms induced by Dex, suggesting the protective effects of LXA~4~ on GC-mediated PE. Furthermore, LXA~4~ treatment improved placental oxidative stress in PE rat mediated by Dex. Placenta oxidative stress represents the fundamental abnormality resulting in PE ([@B21]). We confirmed here deduced placental oxidative stress after LXA~4~ administration in Dex-induced PE rat model that supports the protective roles of LXA~4~ against adverse effects of GC on placental function. HIF1A, overexpressed in hypoxic PE placenta, is implicated in PE pathogenesis ([@B20]; [@B33]; [@B28]). Importantly, we reported that LXA~4~ could suppress HIF1A overexpression in Dex-treated placenta, providing an important mechanistic explanation for the modulation of LXA~4~ on GC in PE.

The human placenta express high levels of 11β-HSD2, the enzyme responsible for GC inactivation ([@B24]; [@B29]; [@B1]). It has been suggested that 11β-HSD2 serves as an effective barrier to protect the placenta and fetus from high concentrations of maternal cortisol ([@B1]). Pregnancies complicated by PE have been associated to a compromised 11β-HSD2 activity and/or availability ([@B1]). We found here that Dex exposure could lead to enhanced 11β-HSD2 expression and corticosterone production in experimental PE rats. However, LXA~4~ could antagonize the effects of GC on11β-HSD2 expression, and, accordingly, inhibit corticosterone production in experimental PE rats. The study demonstrated an additional function of LXA~4~ to inhibit the adverse effects of GC during pregnancy by suppressing 11β-HSD2 expression and GC activity.

PE is attributed to impaired trophoblast development, called poor placentation ([@B22]; [@B5]). We confirmed previously that GC exposure in early pregnancy could result in PE in rats *via* inhibiting trophoblast development ([@B35]). We showed here that Dex could promote trophoblast apoptosis while suppress trophoblast proliferation. However, LXA~4~ could antagonize the effects of Dex on trophoblast apoptosis and proliferation. Our results suggest that LXA~4~ could ameliorate the inhibitory effects of Dex on trophoblast development, supporting the protective roles of LXA~4~ in placentation against GC and providing another important mechanistic explanation for the counterregulation of LXA~4~ on GC in PE.

PE, involving complicated mechanisms in its pathogenesis, is thought to be a multifactorial disorder. Thus, the study just demonstrates one of the important mechanisms underlying PE occurrence. It is noteworthy that there may be other factors, including reduction of PPAR activators, imbalance of angiogenic and anti-angiogenic factors, enhancement of pro-inflammatory cytokines, abnormal expressions of microRNAs, and impairment of other SPMs (resolvins, protectins and maresins) ([@B30]; [@B3]; [@B4]), in addition to dampened LXA~4~ that are responsible for GC-mediated PE, and may act in concert to stimulate HIF1A overexpression, placental oxidative stress and PE development reported in the study and other works. Further studies are planned to investigate other detailed mechanisms underlying the regulation of LXA~4~ and GC on these factors during PE. In addition, further studies may be needed to explore other candidate agents, such as statins and placental growth factor (PGF), for enhancing LXA~4~ biosynthesis and PE treatment, since pravastatin has been demonstrated to induce PGF and ameliorate PE in a mouse model ([@B10]).

By employing clinical data, the present study demonstrated the correlation between GC and LXA~4~ in human PE. Relying on the findings gathered by employing GC-induced PE rat model and trophoblast model, the study provides further evidence that GC/LXA~4~ axis is involved in PE pathogenesis. The study demonstrates a common mechanism underlying PE occurrence, providing new insights into the better understanding of PE. Our data reveal a previously unappreciated facet of LXA~4~ biofunctions, implicating the endogenous lipid mediator in novel immunoendocrine crosstalk mechanisms during PE. These findings suggest that administration of LXA~4~ and avoidance of stress or GC exposure might represent potential strategies to prevent PE, and also contribute to develop other therapeutic strategies to treat PE.
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